The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv.

Amelio, I., Gostev, M., Knight, R., Willis, A., Melino, G., Antonov, A. (2014). DRUGSURV: A resource for repositioning of approved and experimental drugs in oncology based on patient survival information. CELL DEATH & DISEASE, 5(2), e1051 [10.1038/cddis.2014.9].

DRUGSURV: A resource for repositioning of approved and experimental drugs in oncology based on patient survival information

Amelio, I;MELINO, GENNARO;
2014-01-01

Abstract

The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv.
2014
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA
English
Antineoplastic Agents; Clinical Trials as Topic; Computational Biology; Databases, Factual; Drug Approval; Drug Evaluation; Humans; Internet; Neoplasms; Drug Repositioning
Amelio, I., Gostev, M., Knight, R., Willis, A., Melino, G., Antonov, A. (2014). DRUGSURV: A resource for repositioning of approved and experimental drugs in oncology based on patient survival information. CELL DEATH & DISEASE, 5(2), e1051 [10.1038/cddis.2014.9].
Amelio, I; Gostev, M; Knight, R; Willis, A; Melino, G; Antonov, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/131995
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 85
  • ???jsp.display-item.citation.isi??? 76
social impact